VALNEVA SE (VLA.PA)

FR0004056851 - Common Stock

3.28  -0.19 (-5.53%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VLA. VLA was compared to 81 industry peers in the Biotechnology industry. Both the profitability and financial health of VLA have multiple concerns. VLA is valied quite expensively at the moment, while it does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

VLA had negative earnings in the past year.
VLA had a negative operating cash flow in the past year.
In the past 5 years VLA always reported negative net income.
In multiple years VLA reported negative operating cash flow during the last 5 years.

1.2 Ratios

VLA has a Return On Assets (-33.43%) which is comparable to the rest of the industry.
With a Return On Equity value of -119.91%, VLA is not doing good in the industry: 64.47% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -33.43%
ROE -119.91%
ROIC N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 36.83%, VLA perfoms like the industry average, outperforming 55.26% of the companies in the same industry.
In the last couple of years the Gross Margin of VLA has declined.
VLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%

1

2. Health

2.1 Basic Checks

VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VLA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VLA has more shares outstanding
Compared to 1 year ago, VLA has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -1.17, we must say that VLA is in the distress zone and has some risk of bankruptcy.
VLA has a Altman-Z score of -1.17. This is comparable to the rest of the industry: VLA outperforms 43.42% of its industry peers.
A Debt/Equity ratio of 1.26 is on the high side and indicates that VLA has dependencies on debt financing.
VLA has a Debt to Equity ratio of 1.26. This is in the lower half of the industry: VLA underperforms 68.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Altman-Z -1.17
ROIC/WACCN/A
WACC6.85%

2.3 Liquidity

VLA has a Current Ratio of 1.65. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
VLA's Current ratio of 1.65 is on the low side compared to the rest of the industry. VLA is outperformed by 60.53% of its industry peers.
A Quick Ratio of 1.37 indicates that VLA should not have too much problems paying its short term obligations.
VLA has a Quick ratio of 1.37. This is in the lower half of the industry: VLA underperforms 63.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.37

5

3. Growth

3.1 Past

VLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.19%, which is quite impressive.
VLA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.29%.
The Revenue has been growing slightly by 6.34% on average over the past years.
EPS 1Y (TTM)83.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%415.38%
Revenue 1Y (TTM)-59.29%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%-2.25%

3.2 Future

The Earnings Per Share is expected to grow by 35.16% on average over the next years. This is a very strong growth
VLA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.69% yearly.
EPS Next Y119.02%
EPS Next 2Y25.23%
EPS Next 3Y20.92%
EPS Next 5Y35.16%
Revenue Next Year22.09%
Revenue Next 2Y13.56%
Revenue Next 3Y18.18%
Revenue Next 5Y22.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

1

4. Valuation

4.1 Price/Earnings Ratio

VLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

VLA's earnings are expected to grow with 20.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.23%
EPS Next 3Y20.92%

0

5. Dividend

5.1 Amount

VLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

VALNEVA SE

EPA:VLA (6/14/2024, 7:00:00 PM)

3.28

-0.19 (-5.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap228.21M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.43%
ROE -119.91%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 36.83%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.65
Quick Ratio 1.37
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)83.19%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y119.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-59.29%
Revenue growth 3Y11.69%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y